Abstract
Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:TNF as a Target of Inflammation in Rheumatoid Arthritis
Volume: 15 Issue: 2
Author(s): Hisashi Yamanaka
Affiliation:
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Abstract: Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Export Options
About this article
Cite this article as:
Yamanaka Hisashi, TNF as a Target of Inflammation in Rheumatoid Arthritis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316121808
DOI https://dx.doi.org/10.2174/1871530315666150316121808 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GLUT4 Goes Abnormal: Disregulation of the Insulin-Responsive Glucose Transporter in Abnormal Metabolic States
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia
Current Pharmacogenomics The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design FDG-PET/CT in Rheumatoid Arthritis: A Review
Current Molecular Imaging (Discontinued) Association Study of IL-4 -590 C/T and DDX39B -22 G/C Polymorphisms with the Risk of Late-Onset Alzheimer’s Disease in Iranian Population
Current Aging Science Use of Non-steroidal Anti-inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn
Current Drug Metabolism Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Current Topics in Medicinal Chemistry An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy
CNS & Neurological Disorders - Drug Targets Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Current Medicinal Chemistry Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry Advanced Drug Delivery Systems for Transdermal Delivery of Non-Steroidal Anti-Inflammatory Drugs: A Review
Current Drug Delivery